VOLUME: niVOLUMab in real clinical practice in patients with squamous cell carcinoma of the head and neck (SCCC)
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)
- Execution start: 16/10/2020
- End of execution: 31/07/2021
- PI: JOAQUINA MARTINEZ GALAN